Tumores Gastrintestinais
Estudo randomizado | Cirurgia exploratória laparoscópica de nodo sentinela para preservar o estômago de pacientes com câncer gástrico inicial.
11 Abr, 2022 | 12:35h
Comentário no Twitter
In a phase III noninferiority trial of laparoscopic sentinel node navigation surgery vs standard gastrectomy for gastric cancer, 3-year DFS was 91.8% vs 95.5%, but with fewer complications, better physical function, improved nutrition & similar DSS/OS: https://t.co/A7Z8tejiIA
— NatureRevClinOncol (@NatRevClinOncol) March 30, 2022
Riscos relativos e atribuíveis de câncer gástrico cárdico e não cárdico associados com infecção por Helicobacter pylori na China.
8 Abr, 2022 | 21:32hComentário: Helicobacter pylori infection and risk of gastric cancer – The Lancet Public Health
Estudo de coorte | Desfechos para receptor e doador após transplante hepático com doador vivo para metástases hepáticas colorretais irressecáveis.
8 Abr, 2022 | 17:06hComentários:
Living-Donor Liver Transplant Promising for CRC With Liver Mets – HealthDay
Comentário no Twitter
Study suggests living-donor liver transplant is a promising option for meticulously selected patients with unresectable colorectal cancer liver metastases. https://t.co/p6Jbzb73DL
— JAMA Surgery (@JAMASurgery) March 30, 2022
Revisão | Avanços na terapia do adenocarcinoma de ducto pancreático.
8 Abr, 2022 | 17:00hTranslational advances in pancreatic ductal adenocarcinoma therapy – Nature Cancer (se o acesso a este link for pago, tente este)
Comentário no Twitter
🔥Don't miss this beautiful review @NatureCancer on translational advances in pancreatic ductal adenocarcinoma by #AbdelNasserHosein, #StephanieKDougan, #AndrewJAguirre & @Aiims1742
Read it here🔥👇https://t.co/t6CWD0KCoxhttps://t.co/6RjCQ5NqNo
— Nature Cancer (@NatureCancer) March 29, 2022
Diretriz ACG | Diagnóstico e tratamento do esôfago de Barrett.
5 Abr, 2022 | 12:05hSeguimento de longo prazo de estudo randomizado | Nivolumabe com quimioterapia ou ipilimumabe no câncer gastroesofágico.
1 Abr, 2022 | 12:52hNivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer – Nature
Estudo original: RCT: First-line nivolumab plus chemotherapy vs. chemotherapy alone for advanced gastric, gastro-esophageal junction, and esophageal adenocarcinoma.
Comentário no Twitter
New data from CheckMate 649 confirm that the OS benefit of nivolumab added to chemotherapy for advanced-stage gastroesophageal adenocarcinoma persists beyond 24 mo (HR 0.79; 95% CI 0.71-0.88); however, nivo+ipi did not improve OS vs chemotherapy alone: https://t.co/2Pom4zD7oX
— NatureRevClinOncol (@NatRevClinOncol) March 25, 2022
Diretriz clínica SEOM-GEMCAD-TTD | Diagnóstico e tratamento de câncer esofágico.
1 Abr, 2022 | 11:58hEstudo de coorte | Fatores de risco para complicações após cirurgia para tumores neuroendócrinos pancreáticos.
31 Mar, 2022 | 13:04hRisk factors for complications after surgery for pancreatic neuroendocrine tumors – Surgery
Comentário no Twitter
Risk factors for complications after surgery for pancreatic neuroendocrine tumors@hpb_so @NANETS1 @AHPBA @EAHPBA @Cancer_UMCU @UMCU_Intl @me4_so
🆓#openaccess #VisualAbstract
https://t.co/uVNFRqpKKP pic.twitter.com/iIVbQSBawD— SURGERY Journal (@SurgJournal) March 25, 2022
Estudo de coorte | Características e prognóstico da resistência adquirida a imunoterápicos no câncer gastrintestinal.
31 Mar, 2022 | 12:25hComentário convidado: Acquired Immunotherapy Resistance in Gastrointestinal Cancers – JAMA Network Open
Revisão | Tratamento cirúrgico do câncer gástrico.
25 Mar, 2022 | 15:52hSurgical Management of Gastric Cancer: A Review – JAMA Surgery (gratuito por tempo limitado)